Fig. 3. In vivo anti-cancer efficacy of recombinant Bacillus Calmette–Guérin containing the streptococcal inhibitor of the complement gene (rBCG-sic) in the orthotopic bladder cancer mouse model. (A) Schematic summary of the intravesical instillation in the orthotopic bladder cancer mouse model. (B) Representative in vivo imaging via bioluminescence signaling in the mouse bladder after intravesical mock BCG and rBCG-sic instillation. (C) Changes in tumor volume via signal intensity in mouse bladder after intravesical serial mock BCG and rBCG-sic instillation. (D) Body weight changes of the mice after intravesical serial mock BCG and rBCG-sic instillation. Data are the mean±SE (n=3–5 per group). ^*p<0.05 vs. phosphate-buffered saline (PBS), ^**p<0.01 vs. PBS, ^#p<0.05 vs. mock BCG 30 multiplicities of infection (MOI).